Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial

Shao-xiang Xian; Zhong-qi Yang; Pei-hua Ren; Xiao-han Ye; Sui-lin Ye; Qing-hai Wang; Zhao-hui Wang; Shu-jing Shen; Xi-wen Huang

doi:10.1007/s11655-015-2170-x

Your Location：

Home >

Browse articles >

Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial

Updated：2021-08-27

- Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial
- Chinese Journal of Integrative Medicine Vol. 21, Issue 10, Pages: 733-742(2015)
- Affiliations：
  
  1. The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine,Guangzhou,China
  2. The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,China
  3. Dongguan Hospital of Traditional Chinese Medicine,Dongguan,China
  4. Guangzhou Hospital of Traditional Chinese Medicine,Guangzhou,China
  5. Guangdong Second Traditional Chinese Medicine Hospital,Guangzhou,China
- Author bio：
- Funds：
  
  Supported by Guangzhou Municipal Science and Technology Bureau Key Technology Research and Development of Pharmaceutical Preparations and Industrial Demonstration projects of China (No. 2008A1-E4101)
- DOI：10.1007/s11655-015-2170-x
  CLC：
- Published：2015，
  
  Published Online：6 May 2015，
Scan for full text
Xian, Sx., Yang, Zq., Ren, Ph. et al. Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial., Chin. J. Integr. Med. 21, 733–742 (2015). https://doi.org/10.1007/s11655-015-2170-x

Shao-xiang Xian, Zhong-qi Yang, Pei-hua Ren, et al. Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial. [J]. Chinese Journal of Integrative Medicine 21(10):733-742(2015)
Xian, Sx., Yang, Zq., Ren, Ph. et al. Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial., Chin. J. Integr. Med. 21, 733–742 (2015). https://doi.org/10.1007/s11655-015-2170-x DOI：

Shao-xiang Xian, Zhong-qi Yang, Pei-hua Ren, et al. Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial. [J]. Chinese Journal of Integrative Medicine 21(10):733-742(2015) DOI： 10.1007/s11655-015-2170-x.

摘要

To investigate the safety and efficacy of Yangxinkang Tablets (养心康片) in patients with chronic heart failure (CHF) and syndrome of qi and yin deficiency

blood stasis

and water retention. In a double-blinded

randomized

placebo-controlled

multicenter clinical trail

228 patients with CHF New York Heart Association (NYHA) class II or III in stage C were assigned by randomized block method to two groups in a 1:1 ratio to undergo either conventional Western treatment or conventional treatment plus Yangxinkang Tablets for 4 weeks. The outcome measure were effect of cardiac function

Chinese medicine (CM) syndromes

scores of symptoms

signs

and quality of life measured by Minnesota Living with heart failure questionnaire (MLHFQ) before and after the treatment. Totally 112 patients were analyzed in the treatment group and 109 in the control group. They were comparable in NYHA functional class

basic parameters and primary diseases before treatment. Cardiac function and CM syndromes were greatly ameliorated in both groups after treatment. Total effective rates of cardiac function and CM syndrome in the treatment group were significantly higher than those in the control group (P<0.05). Total symptom score and sign score in the treatment group decreased significantly after treatment (P<0.01)

which were significantly lower than those in the control group (P<0.05). There were statistically significant differences in post-treatment scores of gasp

cough with phlegm

pulmonary rales and jugular vein engorgement between the two groups (P<0.05 or P<0.01). Three MLHFQ scores decreased significantly in both groups after treatment (P<0.01). Post-treatment total scale score and physical subscale score in the treatment group and the reduction of them showed statistically significant differences (P<0.05) as compared with the control group. There was no significant difference between the two groups in emotional subscale score and the reduction after treatment (P>0.05). There was no obvious adverse reaction in either group noted during the study. Yangxinkang Tablets were safe and efficacious in improving cardiac function

CM syndromes

symptoms

signs

and quality of life in patients with CHF class II or III in stage C on the base of conventional treatment.

Abstract

To investigate the safety and efficacy of Yangxinkang Tablets (养心康片) in patients with chronic heart failure (CHF) and syndrome of qi and yin deficiency

blood stasis

and water retention. In a double-blinded

randomized

placebo-controlled

multicenter clinical trail

Chinese medicine (CM) syndromes

scores of symptoms

signs

which were significantly lower than those in the control group (P<0.05). There were statistically significant differences in post-treatment scores of gasp

cough with phlegm

CM syndromes

symptoms

signs

and quality of life in patients with CHF class II or III in stage C on the base of conventional treatment.

关键词

chronic heart failureChinese Medicinecardiac functionsyndromequality of life

Keywords

chronic heart failureChinese Medicinecardiac functionsyndromequality of life

references

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240–e327.

Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118–2121.

Chinese Society of Cardiovascular Diseases in the Chinese Medicine Association, Editing Committee of Chinese Journal of Cardiology. 2010 Guideline for the diagnosis and management of acute heart failure. Chin J Cardio (Chin) 2010;38:195–208.

Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer Five year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315–22.

China Food and Drug Administration. Good clinical practice. [S/OL]. (2003–08-06) [2014–09-17]. http://www.sfda.gov.cn/ WS01/CL0053/24473.html.

Chen HZ, Clinical cardiology Shanghai: Shanghai Medical University Press; 1992:233.

Bei ZP. 3200 medical disease diagnostic criteria. Beijing: Science Press; 1998:5.

The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Boston, Mass: Little and Brown Co; 1994.

Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganinats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005;112:e154–e235.

Zheng XY, Guiding principles for clinical research on new drugs of traditional Chinese medicine. Beijing: Chinese Medical Science and Technology Press; 2002:77–84.

Carvalho VO, Guimarães GV, Carrara D, Bacal F, Bocchi EA. Validation of the Portuguese version of the Minnesota Living with Heart Failure Questionnaire. Arq Bras Cardiol 2009;93:39–44.

Liu R, Bai RH. Implementation of Ridit analysis by SPSS. Chin Health Statist (Chin) 2004;21:236–237.

Zou X, Wu HL, Deng TT. Pearls of wisdom, experience of professor Deng Tietao in the treatment of congestive heart failure. Study J Tradit Chin Med (Chin) 2004;4:583.

Yin KC, Wu HL. Experience of Professor DENG Tie-tao in treatment of heart failure by regulating spleen and protecting heart. New Tradit Chin Med (Chin) 2002;34:11.

Dong XB, Kong L. Discussion of the pathogenesis evolvement of chronic heart failure in traditional Chinese medicine. Global Tradit Chin Med (Chin) 2011;4:201–203.

Zou X, Pan GM, Sheng XG. Clinical epidemiological survey on TCM syndrome rules of chronic heart failure. Chin J Integr Tradit West Med (Chin) 2011;31:903.

Miao Y, Wang PJ. Discussion of the combination of disease and syndrome and the clinical treatment of chronic heart failure. Chin J Integr Tradit West Med (Chin) 2011;31:1306.

Huang YS, Xian SX, Ding YQ. Clinical study on the treatment of Baoxinkang in patients with qi-yang deficiency syndrome. Tradit Chin Drug Res and Clin Pharm (Chin) 2000;11:261–265.

Zhu YB, Lin L, Du JM. Study and clinical usage of Minnesota Living with Heart Failure Questionnaire Chinese version. Chin J Behav Med Brain Sci (Chin) 2010;19:178–181.

Tsuey-Yuan H, Debra K M, Shiow-Li H, Terry AL, Misook LC. Comparison of health-related quality of life between American and Taiwanese heart failure patients. J Transcult Nurs 2010;21:212–219.

Debra KM, Laura Y, Jie LS, Ginger AC, Karen AH, Judith AG. Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. J Card Fail 2009;15:763–769.

Zhu YB, Lin L, Du JM. Survey on health related quality of life. Chin J Behav Med Sci (Chin) 2008, 17:982–984.

Deng HH. Quality of life in patients with chronic heart failure and infl uence factors. J Chongqing Med Univ (Chin) 2009;34:783–785.

Zuazagoitia A, Grandes G, Torcal J, Lekuona I, Echevarria P, Gó mez MA, et al. Rationale and design of a randomized controlled trial evaluating the effectiveness of an exercise program to improve the quality of life of patients with heart failure in primary care: the EFICAR study protocol. BMC Public Health 2010;10:33.

FULL TEXT LINK

More>

Views

101

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Standardized treatment of chinese medicine decoction for cancer pain patients with opioid-induced constipation: A multi-center prospective randomized controlled study

Effectiveness of Bufei Yishen Granule (补肺益肾颗粒) combined with acupoint sticking therapy on quality of life in patients with stable chronic obstructive pulmonary disease

Chinese medicine improves postoperative quality of life in endometriosis patients: A randomized controlled trial

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Effect of traditional and integrative regimens on quality of life and early renal impairment in elderly patients with isolated systolic hypertension

Related Author

No data

Related Institution

Department of Oncology, First Affiliated Hospital of Guangzhou University of Chinese Medicine

Dongzhimen Hospital, Beijing University of Chinese Medicine

The Geriatric Department, Henan University of Traditional Chinese Medicine

Department of Respiratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Department of Respiratory, the First Affiliated Hospital of Anhui College of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰